Nectar Lifesciences (LUX:NECLF) LT-Debt-to-Total-Asset : 0.06 (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Nectar Lifesciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nectar Lifesciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.06.

Nectar Lifesciences's long-term debt to total assets ratio declined from Mar. 2023 (0.10) to Mar. 2024 (0.06). It may suggest that Nectar Lifesciences is progressively becoming less dependent on debt to grow their business.

Nectar Lifesciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Nectar Lifesciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences LT-Debt-to-Total-Asset Chart

Nectar Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.12

0.10

0.06

Nectar Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	-	0.09	-	0.06

Nectar Lifesciences LT-Debt-to-Total-Asset Calculation

Nectar Lifesciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	16.9	/	263.915
	=	0.06

Nectar Lifesciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	16.9	/	263.915
	=	0.06

Nectar Lifesciences (LUX:NECLF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nectar Lifesciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nectar Lifesciences (LUX:NECLF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (LUX:NECLF) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

NECLIFE:India 532649:India

Address

SCO 38-39, Sector 9d, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009

Website

https://www.neclife.com

Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences (LUX:NECLF) Headlines

No Headlines